JPSIM Journal of Pakistan Society of Internal Medicine J Pak Soc Intern Med 2709-8729 2710-0804 Pakistan Society of Internal Medicine 10.70302/jpsim.v6i4.2562 jpsim.v6i4.2562 Original Research Comparison of efficacy of Erythropoietin Alpha with Erythropoietin Beta in Treatment of Anemia in Patients of End Stage Renal Disease on Hemodialysis Javaid Bilal dr.bilaljavaid160@gmail.com * Irfan Muhammad Hassan Sumaira Nabi Ijaz Rehman Fatima Allied Hospital, Faisalabad Medical University, Faisalabad *Correspondence: Bilal Javaid (dr.bilaljavaid160@gmail.com) 21 11 2025 2025 6 4 336 339 03 02 2025 15 04 2025 11 10 2025 Copyright © 2025 The Author(s) 2025 The Author(s) https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective

To compare the efficacy of erythropoietin (EPO) alpha with erythropoietin beta in treatment of anemia in patients of end stage renal disease (ESRD) on hemodialysis.

 Methodology

This Prospective Cohort was carried out in the Department of Nephrology, Allied hospital, Faisalabad from 11/06/2022 to 10/12/2022. 170 patients meeting the selection criteria were enrolled. Group A patients received erythropoietin alpha for 3 months. Group B patients received erythropoietin beta for 3 months. The dosage was administered subcutaneously. Efficacy was assessed after 3 months of treatment as per the operational definition.

 Results

Mean age in Group A was 45.79+10.91 and in Group B 44.74+11.28 years. Mean BMI of the patients in Group A was 27.36+2.69 and in Group B 27.42+2.83. Mean duration of dialysis in Group A was 2.91+1.18 years and in Group B 2.87+1.14 years. Efficacy in Group A was 17(20%) and in Group B 38(44.7%).

 Conclusion

The study concluded that erythropoietin beta is better than erythropoietin alpha in treatment of anemia in patients of ESRD on hemodialysis.

 Keywords End stage renal disease (ESRD) anemia erythropoietin alpha hemodialysis erythropoietin beta efficacy. Ethics Statement

Ethics committee: Ethical Review Committee, Faisalabad Medical University, Faisalabad, Pakistan. Approval number: 48.ERC/FMU/2021-22/256, dated March 17, 2023.

 References Shahab MH, Khan SS. Erythropoietin administration for anemia due to chronic kidney disease-subcutaneous OR intravenous, what do we know so far? Cureus. 2020;12(9):e10358. Goldsmith D, Dellanna F, Schiestl M, Krendyukov A, Combe C. Epoetin biosimilars in the treatment of renal anemia: what have we learned from a decade of European experience? Clin Drug Invest. 2018;38(6):481-90. El-Ashmawy NE, Khedr EG, Kotb NS, Salem F, Ibrahim AO. Comparative efficacy and safety study of darbepoetin alfa versus epoetin alfa in management of anemia associated with ESRD in Egyptian hemodialysis patients. Curr Drug Safety. 2022;17(3):250-8. Al-Saedi AJH, Karim AHA. Effect of erythropoietin in treatment of renal anemia in a sample of Iraqi patient. Al Ameen J Med Sci. 2021;14(1):68-71. Ahsan MN, Asif N, Khanzada SW, Asghar MS, Yasmin F, Khalid F, et al. Comparative effectiveness of erythropoietin alpha and beta in hemodialysis patients: a single-center prospective observational study. J Community Hospital Inten Med Persp. 2021;11(6):782-6. Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037-48. Karimi Z, Shahraki HR, Mohammadian-Hafshejani A. Erythropoiesis-stimulating agents and cardiovascular mortality: A systematic review and meta-analysis of 17 studies and 372,156 hemodialysis patients. Int J Cardiol Cardiovasc Risk Preven. 2023; 10.1016/j.ijcrp.2023.200220. Dashti S, Dhrolia M, Qureshi R, Nasir K, Ahmad A. Therapeutic Efficacy of Erythropoietin Alpha and Erythropoietin Beta in Anemia of Chronic Kidney Disease. J Col Phy Surg Pak. 2021;31(12):1417-21. Osmanovic E, Cerkezovic M, Jagodic A. Blood Count Under the Effect of Erythropoietin (EPO) in Patients with Chronic Hemodialysis. Am J Intern Med. 2022;10(1):8-12. Muhammad-Baqir BM, Hameed EN, Shareef RH, Ahmed MH. Impact of erythropoietin on anemia in end-stage renal disease patients on hemodialysis. Med J Babylon. 2023;20(3):558-63. Ostrvica E, Mesic E, Ostrvica D, Delic J, Delic-Custendil S, Hukic F. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta. Med Arh. 2010;64(1):4-6. Omrani H-R, Golmohhamadi S, Hashemian A-H, Vaysmoradi A-Z, Safari-Faramani R. Therapeutic efficacy of erythropoietin alfa and erythropoietin beta in hemodialysis; a randomized controlled trial. J Renal Injury Preven. 2018;8(1):44-9. Loughnan A, Ali GR, Abeygunasekara SC. Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients. Renal Failure. 2011;33(3):373-5. Azmandian J, Abbasi MR, Pourfarziani V, Nasiri AA, Ossareh S, Ezzatzadegan Jahromi S, et al. Comparing therapeutic efficacy and safety of epoetin beta and epoetin alfa in the treatment of anemia in end-stage renal disease hemodialysis patients. Am J Nephrol. 2018;48(4):251-9. Prasetya A, Suprapti B, Shanti BD. Effectivity of erythropoietin alpha compared to erythropoietin beta in patients with chronic kidney disease-anemia on hemodialysis. Folia Medica Indonesiana. 2021;55(2):82-8.